Active Green Tea
Longevity enhancing antioxidant
- Potent green tea leaf extract, high in EGCg
- Enhances weight loss by boosting metabolism
- Potent anti-aging effects
- Research backed dose
Green tea provides powerful antioxidants, promotes longevity, cardiovascular health, healthy weight management, healthy cellular growth & differentiation, liver health, and more. AOR™ Active Green Tea is a high-potency standardized extract of green tea, high in epigallocatechin gallate (EgCG), believed to be the key phytonutrient responsible for green tea’s health benefits. Studies most consistently report health benefits in persons drinking 10 cups a day of high-EgCG sencha-style Japanese green tea; each cup of this tea contains 150 milligrams of EgCG. The labels of most green tea extracts exaggerate the number of cups of tea represented in their capsules by comparing the product to poor-quality teas. AOR™ Active Green Tea allows you to more fully enjoy the healthy properties of a sencha-rich lifestyle without consuming large volumes of tea. Active Green Tea also contains a tiny amount of caffeine to optimize its benefits while minimizing any negative effects from caffeine.
In just three capsules, Active Green Tea provides the equivalent of 10 cups of sencha green tea, the amount research has shown to be associated with the greatest health benefits. Active Green Tea contains a small amount of caffeine, just enough for maximum synergistic health benefits but without the side effects.
Green tea catechins help protect plasma and lipoproteins from oxidative damage by increasing blood antioxidant capacity.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal by product.
To equate the EGCg consumption of the best Japanese studies, take one capsule three times daily with food, or as directed by a qualified health care practitioner.
Consult a Healthcare practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner for use beyond 12 weeks, if you have a liver disorder, or if you have an iron deficiency. Rare, unpredictable cases of liver injury associated with green tea extract-containing products have been reported (in Canada and internationally). Discontinue use if you develop symptoms of liver trouble, such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite and consult a health care practitioner.
- Normal cell growth and differentiation
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with a health care practitioner if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Non-medicinal Ingredients: ascorbyl palmitate, sodium stearyl fumarate. Capsule: hypromellose.
A study published in 2007 aimed to investigate the effects of green tea supplementation, with decaffeinated green tea extracts on hemodialysis induced reactive oxygen species, atherosclerotic risk factors and pro-inflammatory cytokines. This study included 6 healthy participants and 54 hemodialysis patients, who were given 0, 455 or 910 mg green tea catechins during hemodialysis to observe the antioxidant effects of this supplementation. Participants also participated in a 7-month interventional study, which compared green tea catechins to a placebo.
The results show a significant reduction in pro-inflammatory cytokine expression enhanced by hemodialysis, compared to the placebo group. Additionally, catechin supplementation was associated with less pre-dialysis hydrogen peroxide activity, c-reactive protein and pro-inflammatory cytokine concentrations, compared to the patients on the placebo.
Healthy volunteers consumed 300 mg green tea extract for 14 days and whole blood was obtained and studied for its antioxidant capacity, in this study published in 2015. After 14 days of green tea extract consumption, there was a significant increase in the release of myeloperoxidase and lactoferrin when whole blood was stimulated with fMet-Leu-Phe, which activates a number of leukocytes including mature neutrophils and monocytes. This was mirrored by a significant increase in the total antioxidant status after 14 days of green tea ingestion, indicating that supplementation with green tea extract for 14 days can increase the leukocyte activity and the total plasma antioxidant status and may have role to play in the prevention of inflammatory disease.
A single-blind, randomized, controlled clinical study out of the University of Oklahoma, evaluated the effects of green tea supplementation on antioxidant parameters in adults with metabolic syndromes. Participants were randomly assigned to one of the following groups: 1) green tea, 4 cups/day; 2) control, 4 cups water/day; or 3) green tea extract, 2 capsules and 4 cups water/day for 8 weeks. For the duration of the study, blood samples were collected at specific intervals and the following markers were measured: Circulating carotenoids (alpha-, beta-carotene, lycopene) and tocopherols (alpha-, gamma-tocopherols), and trace elements. Serum antioxidant enzymes (glutathione peroxidase, glutathione, catalase) and plasma antioxidant capacity was also measured spectrophotometrically. The results show that both green tea beverage and extract significantly increased the antioxidant capacity of the plasma and whole blood glutathione levels, compared to the control group.
A meta-analysis of randomized, placebo-controlled clinical studies evaluated the benefits of green tea supplementation (by beverages or supplements) in reducing the risk of breast cancer or its recurrence. Studies were published between 1998 and 2009, and included 5617 cases of breast cancer. In the studies included in this meta-analysis, increased green tea consumption (>3 cups per day) was inversely associated with breast cancer recurrence. Case-controlled studies of breast cancer incidence did suggest an inverse relationship, although no association was found among cohort studies of breast cancer incidence, therefore the authors conclude that the available epidemiologic evidence is in support of green tea consumption for reducing the risk of breast cancer recurrence. The authors also ask for more evidence on the relationship between the consumption of green tea and breast cancer incidence, as the studies reviewed were unable to confirm this hypothesis.
A prospective study in Japanese men aimed to evaluate the role of green tea consumption in prostate cancer risk. This cohort study was established in 1990 for cohort I and in 1993 for cohort II and evaluated 49,920 men, aged 40 to 69. The participants were followed up until 2004, where the researchers show 404 newly diagnosed prostate cancer cases (114 advanced, 271 localized and 19 at an undetermined stage). Green tea was not associated with localized prostate cancer. However, consumption was associated with a dose-dependent decrease in the risk of advanced prostate cancer.
A dose-response meta-analysis was published in 2017 to evaluate the relationship between tea consumption, especially green tea, and colorectal cancer risk, reviewing 29 peer-reviewed publications. Results revealed that green tea conferred a protective effect among female and rectal cancer patients. The dose response analysis showed a significant inverse relationship between the consumption of increments of 1 cup/day green tea and colorectal cancer risk.
Another Japanese study looked at the effect of green tea consumption on cancer incidence in all sites in a prospective cohort study that followed participants for 9 years. 8,552 individuals, over 40 years, were followed for the 9 year period. In this study, a total of 384 cases of cancers in all sites were identified. The results show an inverse relationship between green tea consumption and cancer incidence, especially in females drinking ≥ 10 cups per day. The authors believe that the slowdown in the increase of cancer incidence with age observed among females who consumed more than 10 cups a day is consistent with the finding that increased consumption of green tea is associated with later onset of cancer.
A systematic review and meta-analysis of human clinical trials aimed to analyze the effect of green and black tea on endometrial cancer risks. A clear effect of green tea but not black tea was observed as a reduced risk of endometrial cancers. The authors showed that an increase in green tea consumption of one cup per day was associated with an 11% decreased risk of developing endometrial cancer, requiring larger population and cohort studies on endometrial cancer risk to be conducted.
One of the earliest and biggest cohort studies on green tea consumption and cardiovascular mortality was published in 2006. This study (The Ohsaki Study) investigated the associations between green tea consumption and all-cause and cause-specific mortality, specifically stroke, coronary heart disease and cancer. Participants were followed up for 11 years for all-cause mortality and for up to 7 years for cause-specific mortality.
The follow-up rate was over 86% in all groups, with 892 participants dying of cardiovascular disease and 1134 dying of cancer. The authors of this study conclude that green tea consumption was inversely associated with mortality due to all causes and cardiovascular disease, with a stronger association found in women for all-cause mortality and the relationship with cardiovascular disease stronger than that with all-cause mortality. This relationship was not found in mortality due to cancer.
A public health center-based study in Japan evaluated 82,369 Japanese men and women, aged 40 to 59 (cohort I, started in 1990) and 40 to 69 (cohort II, started in 1993), for incidences of strokes, and the impact of green tea and coffee consumption on this incidence. Participants were followed up for about 13 years through a self-administered food frequency questionnaire.
Green tea and coffee consumption were obtained from the frequencies and amount of each beverage consumed using the choice of 0, 1 to 2, 3 to 4, and 5 to 6 times/week, and almost daily (further divided into 1, 2–3, 4–6, 7–9, and ≥10 cups/day). Higher green tea consumption was associated with inverse risks of cardiovascular diseases and stroke subtypes in the general population. Coffee consumption was also associated with this inverse relationship to a slightly lesser degree.
The evidence for the effect of green tea beverages and extraction on cholesterol levels is still undergoing evaluation. A meta-analysis, published in 2011, reviewed the evidence from 14 randomized clinical trials, with 1136 human subjects who consumed green tea beverages and extracts. Results from trials showed that green tea consumption was associated with significantly lowered LDL cholesterol concentrations, with no significant changes observed in HDL cholesterol levels. The meta-analysis also carried out a sub-group and sensitivity analysis to determine if the results obtained were influenced by any factors. The analysis showed that the results were not influenced by the type of intervention, treatment dose of green tea catechins, study duration, individual health status or quality of the study. this suggests that daily consumption of green tea beverages can confer health benefits through the reduction in “bad” LDL cholesterol levels.
A systematic review published in 2016, reviewed the evidence for green tea supplementation on anthropometric, blood pressure and other biochemical measures associated with cardiovascular disease risk. To be included in this review, the clinical studies had to be published in peer-reviewed journals in English and be human double-blind, randomized, placebo-controlled clinical trials. Seven studies met this criteria (out of over 120,000 articles reviewed). The results of this review and analysis showed a consistent and significant reduction in body mass index, blood pressure and plasma lipids, further confirming the role of green tea catechins in promoting cardiovascular health.
This meta-analysis reviewed 15 randomized, placebo-controlled clinical trials for weight loss and 3 studies for weight maintenance, in which various preparations of green tea beverages or controls were given to participants. A total of 1945 participants completed the studies, which ranged from 12 to 13 weeks. The results show a reduction in measurements of weight loss, including body mass index and waist circumference. This analysis concludes that the results are not statistically significant, which could be due to the differences in the preparations of green tea beverages, which were not uniform across the studies.
In this randomized placebo‐controlled trial, 182 moderately overweight Chinese subjects were randomized into one of four groups. Group 1 consumed two servings of a control drink, containing 30 mg catechins, 10 mg caffeine/day. Group 2 consumed one serving of the control drink and one serving of an extra high‐catechin green tea (458 mg catechins, 104 mg caffeine) per day; Group 3 consumed two servings of a high‐catechin green tea (468 mg catechins, 126 mg caffeine) per day; Group 4 consumed two servings of the extra high‐catechin green tea (886 mg catechins, 198 mg caffeine) per day. All groups were on their interventions for 90 days and were observed for weight loss markers, including estimated intra-abdominal fat, waist circumference and total body weight. The results show a decrease in estimated intra-abdominal fat, waist circumference and body weight in the highest catechin consumption group. Reductions in body fat and body fat percentage were observed even in the lower green tea supplementation group.
In a randomized, double-blind, controlled clinical trial, generally healthy, normally sedentary men and women were randomized to receive either a control beverage or a green tea beverage providing 625 mg catechins for 12 weeks. Both beverages contained water, sodium chloride, artificial citrus flavoring, glucose, erythritol, and sucralose, with the catechin group containing green tea extract and the placebo group containing caffeine to match the caffeine content of the green tea catechin beverage.
Participants were asked to maintain constant energy intake and engage in moderate-intensity exercise for about 180 minutes per week. Body composition, abdominal fat and clinical biomarkers were employed to measure any effects. The results show a trend towards weight loss in the green tea catechins group, compared to the placebo group. Changes were observed in the total abdominal fat area, subcutaneous abdominal fat area and fasting serum triglycerides in the green tea catehcin group, compared to the placebo group, suggesting that green tea catechins can enhance exercise-induced weight loss.
A meta-analysis published in 2009 aimed to elucidate whether green tea does indeed have an effect on body weight regulation. This analysis included 11 randomized, controlled clinical studies. The results of this meta-analysis show that an EGCG–caffeine mixture has an effect on weight loss and on weight management after a period of negative energy balance. The impact of ethnicity and habitual caffeine intake should not be discounted in these effects and all doses of catechins used in the treatment were sufficient to produce the results observed.
A randomized, controlled, prospective clinical trial was published in 2010, which aimed to compare the effects of supplementation with green tea beverages, green tea extracts or placebo controls on body weight, glucose and lipid profiles and markers of oxidative stress and safety in obese participants with metabolic syndrome.
Participants were randomized to receive either control (4 cups water per day), green tea (4 cups per day) or green tea extract (2 capsules and 4 cups water per day) for 8 weeks; both the beverage and extract groups were consuming the same dose of EGCG per day.
The results of this study show that green tea beverages and extracts caused a significant decrease in body weight and body mass index (BMI), compared to the control group. Green tea consumption was also associated with a decrease in LDL cholesterol and markers of oxidative stress in obese patients with metabolic syndrome.
A double-blind, counterbalanced, within-subject clinical study, with healthy volunteers, investigated whether the intake of green tea extract could modulate effective brain connectivity parameters related to task performance. Participants were given a milk whey-based soft drink with or without 27.5g green tea extract, while undergoing functional magnetic resonance imaging. The findings from this study provide evidence for the beneficial effect of green tea on cognitive functioning, in particular as it pertains to working memory by showing that green tea extract increased the working memory induced modulation of connectivity from the right superior parietal lobule to the middle frontal gyrus. Notably, the magnitude of green tea induced increase in parieto-frontal connectivity positively correlated with improvement in task performance.
A double-blind, placebo-controlled, cross-over clinical trial aimed to assess the effects of green tea polyphenol epigallocatechin gallate (EGCG) on cognitive performance, mood and localised cerebral blood flow (CBF) parameters in healthy human adults. Participants received either placebo or two doses of EGCG (135 and 270 m) in counterbalanced order on separate days and following a 45 minute resting absorption period, participants were tasked with a selection of computerized cognitive tasks that activate the frontal cortex. Cerebral blood flow and hemodynamics were assessed in the frontal cortex as well.
The results show that 135 mg of EGCG resulted in reduced CBF in the frontal cortex, compared to the placebo group, although this reduction was not associated with changes in cognitive performance or mood. 270 mg of EGCG did not have a reducing effect on CBF, cognition or mood.
In a randomized, double-blind, placebo-controlled study, researchers evaluated the effect of green tea extract and L-theanine, a common amino acid found in tea leaves, including green tea, on memory and attention improvement in subjects with mild cognitive impairment (MCI). 91 participants were randomized to receive either a placebo or 1680 mg of green tea extract for 16 weeks. They were assessed using the Mini Mental State Examination-K (MMSE-K) assessment. Neuropsychological tests (Rey-Kim memory test and Stroop color-word test) and electroencephalography were conducted to evaluate the effect of green tea extract on memory and attention.
Results show that green tea extract improved memory and selective attention by significantly increasing the Rey-Kimm memory quotient and word reading in MCI subjects. Brain theta waves, an indicator of cognitive alertness, were increased significantly in the temporal, frontal, parietal, and occipital areas after 3 hours in the eye-open and reading states in MCI patients in the green tea group, suggesting an important role for green tea consumption as an intervention for cognitive improvement.
The effect of green tea polyphenols on skin properties has been established in cell culture and animal models. This study looked to evaluate the benefits of green tea polyphenols in modulating the skin properties of healthy female volunteers. This was a double-blind, placebo-controlled clinical study where participants consumed 1402 mg of total green tea catechins per day or a control beverage for 12 weeks.
The results of this study show that skin structural characteristics, including skin elasticity, roughness, scaling, density and water homeostasis were positively impacted by the consumption of green tea catechins, compared to the control group. In a separate randomized, double-blind, single-dose trial, green tea polyphenols increased blood flow to skin 30 minutes after consumption, showing the benefits of green tea polyphenols in protecting the skin against harmful UV radiation, as well an improvement in overall skin quality.
In an animal study published in 2003, green tea extract or vitamin C and E (alone and in combination), blueberry extract or no treatment was given to mice over a period of 14 weeks. Body weights and collagen glycation, as a measure of collagen aging were used to measure the effectiveness of the treatments, in comparison to controls. The results showed that green tea extract blocked tendon crosslinking and decreased skin pentosidine levels, as a marker of collagen aging by antioxidant mechanism. This effect was also observed in the mice group fed the combination of vitamin C and E.
The effect of green tea extracts on the clinical and histologic characteristics of photoaging were explored in this study. this randomized, placebo-controlled clinical study looked at a combination regimen of 10% green tea cream and 300 mg (twice a day) green tea oral supplementation for 8 weeks. Histologic grading of skin biopsies showed a significant improvement in the elastic tissue content of the green tea group. The study concludes that longer supplementation may be required to clinically observe improvements, outside of the histologic biopsies.
A randomized, double-blind, placebo-controlled clinical study published in 2016 looked at the effect of green tea extract supplementation for 90 days on liver enzymes, in patients with Non-alcoholic fatty liver disease (NAFLD). Patients (N=80) were randomized to receive either 500 mg green tea tablets per day or placebo and their liver enzymes were measured at the beginning of the study, before supplementation commenced, and after supplementation.
The green tea supplementation group showed significant reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) after 12 weeks of supplementation, showing some protective effects of green tea extract on the livers of patients with NAFLD.
Another study from 2013 investigated the effects of green tea consumption in NAFLD patients, after 12 weeks of supplementation. 17 NAFLD patients were randomized in this double-blind, placebo-controlled clinical study to receive either 1080 mg catechins (high density), 200 mg catechins (low density) or placebo control for 12 weeks and monitored for liver enzymes, ALT and AST, as well as body fat measurements and markers of oxidative stress.
Body fat was significantly decreased in the high-density catechin group compared with the placebo and low-density catechin groups after 12 weeks of consumption. All the patients in the high-density catechin group showed a significantly improved liver-to-spleen CT attenuation ratio compared with the placebo and low-density catechin groups after 12 weeks of consumption. The high-density catechin group significantly decreased serum ALT levels and reduced urinary 8-isoprostane excretion compared with the placebo and low-density catechin group after 12 weeks of consumption.